Daily use of consensus interferon: One-year treatment results for chronic hepatitis C patients relapsing or non-responding to previous interferon

Z. Karasu, A. Gurakar, A. Jazzar, H. Wright

Research output: Contribution to journalArticle

Abstract

Background/aim: The optimal dose, duration and frequency of interferon treatment for chronic hepatitis C is not clear. Preliminary hepatitis C virus kinetic studies have suggested that daily interferon is more advantageous than thrice in a week administration. Recently, a synthetic recombinant interferon, consensus interferon, has been approved for clinical application. There is no data available about daily use of consensus interferon. Methods: Our study protocol was designed to investigate the efficacy of long-term (12 month) daily consensus interferon therapy for chronic hepatitis C patients, who have either relapsed or not responded to previous interferon therapy. Eleven patients were included in the study. Results: Overall, eight (72%) patients became serum HCV-RNA negative. Of these, 60% (3/5) were among previous non-responders and 83% (5/6) were among previous relapsers. Conclusions: Our preliminary data suggests that daily use of consensus interferon provides encouraging results in relapsers and non-responders. However, further time is needed to evaluate the sustained response rate.

Original languageEnglish (US)
Pages (from-to)191-195
Number of pages5
JournalTurkish Journal of Gastroenterology
Volume11
Issue number3
StatePublished - Nov 27 2000
Externally publishedYes

Keywords

  • Consensus interferon
  • Hepatitis C

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Daily use of consensus interferon: One-year treatment results for chronic hepatitis C patients relapsing or non-responding to previous interferon'. Together they form a unique fingerprint.

  • Cite this